<DOC>
	<DOCNO>NCT01510899</DOCNO>
	<brief_summary>This open-label , single-dose , parallel-group study investigate pharmacokinetics safety RO4917838 healthy renal impaired subject . Subjects receive single dose RO4917838 .</brief_summary>
	<brief_title>A Study Effect Renal Impairment Pharmacokinetics RO4917838</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>General criterion Body mass index ( BMI ) 18 32 kg/m2 Criteria apply renal impaired subject Adult subject , 1865 year age Part 1 : Subjects end stage renal disease ( ESRD ) , dialysis Part 2 : Subjects severe , moderate mild renal impairment Stable renal function Criteria apply healthy subject Adult subject , 1870 year age General criteria Any condition disease ( renal impairment renal impaired subject ) would render subject unsuitable study , would place subject undue risk Any condition could relapse immediately study History alcohol drug abuse Criteria apply renal impaired subject Evidence unstable clinically significant disease renal impairment Clinically significant liver disease Any major illness ( exception renal impairment ) within 4 week prior study start Criteria apply healthy subject History clinically significant disease ( e.g. , cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>